Serena Marchi

ORCID: 0000-0002-6817-2461
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Influenza Virus Research Studies
  • Respiratory viral infections research
  • SARS-CoV-2 detection and testing
  • Virology and Viral Diseases
  • Mosquito-borne diseases and control
  • Viral Infections and Vectors
  • Vaccine Coverage and Hesitancy
  • COVID-19 epidemiological studies
  • Animal Disease Management and Epidemiology
  • Herpesvirus Infections and Treatments
  • Immune responses and vaccinations
  • Pneumonia and Respiratory Infections
  • Dermatological and COVID-19 studies
  • Dental Research and COVID-19
  • Animal Virus Infections Studies
  • Microscopic Colitis
  • Inflammatory Bowel Disease
  • Respiratory Support and Mechanisms
  • Viral gastroenteritis research and epidemiology
  • Long-Term Effects of COVID-19
  • Poxvirus research and outbreaks
  • Cardiovascular Effects of Exercise
  • Parvovirus B19 Infection Studies

University of Siena
2017-2025

The Seventh Affiliated Hospital of Sun Yat-sen University
2024

Sun Yat-sen University
2024

VisMederi Research
2024

University of Bari Aldo Moro
2024

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"
2024

University of Pisa
2003-2021

Université Paris Cité
2015

Université d'Abomey-Calavi
2015

University of Bologna
2015

The micro-neutralization assay is a fundamental test in virology, immunology, vaccine assessment, and epidemiology studies. Since the SARS-CoV-2 outbreak at end of December 2019 China, it has become extremely important to have well-established validated diagnostic serological assays for this new emerging virus. Here, we present with use wild type virus two different methods read-out. We evaluated performance using human serum samples taken from an Italian seroepidemiological study being...

10.1002/jmv.25986 article EN cc-by Journal of Medical Virology 2020-05-08

A newly identified coronavirus, named SARS-CoV-2, emerged in December 2019 Hubei Province, China, and quickly spread throughout the world; so far, it has caused more than 49.7 million cases of disease 1,2 deaths. The diagnosis SARS-CoV-2 infection is currently based on detection viral RNA nasopharyngeal swabs by means molecular-based assays, such as real-time RT-PCR. Furthermore, serological assays detecting different classes antibodies constitute an excellent surveillance strategy for...

10.1016/j.jim.2020.112937 article EN cc-by Journal of Immunological Methods 2020-11-28

Abstract SARS-CoV-2 symptoms are non-specific and can range from asymptomatic presentation to severe pneumonia. Asymptomatic subjects carrying often remain undiagnosed it is still debated whether they develop immunoglobulins (Ig) how long persist. The aim of this study was investigate the development persistence antibodies against in infected by virus. This follow-up performed on 31 who presented a positive nasal swab or serology (Ig Spike-RBD) first part UNICORN (March 2020) aimed at...

10.1038/s41598-020-77125-8 article EN cc-by Scientific Reports 2020-11-18

Influenza D virus is a novel influenza virus, which was first isolated from an ailing swine in 2011 and later detected cattle, suggesting that these animals may be primary natural reservoir. To date, few studies have been performed on human samples there no conclusive evidence the ability of to infect humans. The aim this serological study assess prevalence antibodies against serum collected Italy 2005 2017. Serum were analysed by haemagglutination inhibition neutralization assays. results...

10.3390/v12010030 article EN cc-by Viruses 2019-12-27

Introduction In early to mid-2022, an unexpected outbreak of Monkeypox virus infections occurred outside the African endemic regions. Vaccines originally developed in past protect against smallpox are one available countermeasures prevent and Orthopoxvirus infections. To date, there few studies on cross-reactivity neutralizing antibodies elicited by previous vaccinia virus-based vaccination and/or infection. The aim this study was evaluate a possible approach performing live-virus...

10.3389/fpubh.2023.1195674 article EN cc-by Frontiers in Public Health 2023-06-21

SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of antibody response in relation to outcome we performed a study hospitalized COVID-19 patients. As comparison also investigated asymptomatic subjects. Study results show that patients produce strong correlation between different viral antigens (spike protein nucleoprotein) among classes (IgA, IgG, IgM neutralizing antibodies). The peak...

10.1371/journal.pone.0253977 article EN cc-by PLoS ONE 2021-07-02

Although it is well known that the older people have been most susceptible to COVID-19, there are conflicting data on susceptibility of centenarians. Two epidemiological study shown centenarians (> 101 years old at time 2020 pandemic peak) more resilient than remaining centenarians, suggesting this resilience might be linked 1918 Spanish Flu pandemic. To gain insight into matter, specifically whether SARS-CoV-2 infection they had affected by, we conducted a retrospective serological study....

10.1186/s12979-024-00450-3 article EN cc-by Immunity & Ageing 2024-06-27

Toxoplasmosis is a worldwide health problem. Infection in pregnant women can result severe fetal morbidity or subclinical neonatal infection; most cases develop ocular and neurological sequelae. The purpose of this serological study was to assess the prevalence Toxoplasma gondii two populations childbearing age Siena (Tuscany, Central Italy) Bari (Apulia, Southern between 2013 2017 group 2016-2017. Serum samples were tested for presence specific anti-Toxoplasma IgG antibodies by commercially...

10.1051/parasite/2019080 article FR cc-by Parasite 2020-01-01

Background. The recently emerged SARS-CoV-2 Omicron variant exhibits several mutations on the spike protein, enabling it to escape immunity elicited by natural infection or vaccines. Avidity is strength of binding between an antibody and its specific epitope. protein binds cellular receptor with high affinity primary target neutralizing antibodies. Therefore, protective antibodies should show avidity. This study aimed at investigating avidity receptor-binding domain (RBD) their activity...

10.1155/2022/4813199 article EN cc-by Journal of Immunology Research 2022-08-31

Influenza D virus (IDV) was first isolated from a swine with respiratory disease symptoms in 2011 the United States. Epidemiological and serological studies support hypothesis that cattle represent natural reservoir of IDV periodical spillover events to other animal hosts. Little is known about seroprevalence humans specific target groups such as veterinarians Italy. This study designed assess prevalence antibodies against two influenza lineages (D/660 D/OK) Italy archived serum samples...

10.1002/jmv.27466 article EN Journal of Medical Virology 2021-11-23

Dogs are known to be susceptible influenza A viruses, although information on D virus (IDV) is limited. We investigated the seroprevalence of IDV in 426 dogs Apulia region Italy during 2016 and 2023. total 14 samples were positive for antibodies, suggesting exposure dogs.

10.3201/eid3005.231401 article EN cc-by Emerging infectious diseases 2024-04-25

Abstract Since May 2022, several countries outside of Africa experienced multiple clusters monkeypox virus (MPXV)‐associated disease. In the present study, anti‐MPXV and anti‐vaccinia (VACV) neutralizing antibody responses were evaluated in two cohorts subjects from general Italian population (one half born before WHO‐recommended end smallpox vaccination 1980, other after). Higher titers (either against MPXV or VACV) observed cohort individuals interruption VACV vaccination. An association...

10.1002/jmv.29728 article EN cc-by Journal of Medical Virology 2024-06-01

The haemagglutination inhibition assay (HAI) and the virus microneutralisation (MN) are long-established methods for quantifying antibodies against influenza viruses. Despite their widespread use, both assays require standardisation to improve inter-laboratory agreement in testing. FLUCOP consortium aims develop a toolbox of standardised serology seasonal influenza. Building upon previous collaborative studies harmonise HAI, this study carried out head-to-head comparison harmonised HAI MN...

10.3389/fimmu.2023.1155552 article EN cc-by Frontiers in Immunology 2023-04-18

The influenza viruses have the ability to agglutinate erythrocytes by binding sialic acid receptors on host cell. Human preferentially bind linked galactose α 2.6 linkage, while avian Gal 2.3 linkage. There is a close correlation between of A from different animal species and their receptor specificity. haemagglutination inhibition assays are influenced erythrocytes. To provide an overview expression erythrocytes, (turkey, chicken, pigeon) mammalian (sheep, horse, human) been analysed flow...

10.15167/2421-4248/jpmh2018.59.1.870 article EN PubMed 2018-03-01

According to the World Health Organization, entire African continent is at risk of a Zika outbreak. To increase data availability on epidemiology virus circulation in Africa, we evaluated immunity selected cohort subjects from West Africa between 2007 and 2012. Human serum samples were collected 2011/2012 2–29-year-old Mali, Senegal, The Gambia. A sample that tested positive by IgG ELISA microneutralization test was defined as positive. In 2007, highest prevalence 21.9%, found Senegal among...

10.3390/v12060641 article EN cc-by Viruses 2020-06-13

In the absence of effective drugs or vaccines for treatment five Dengue Virus serotypes, search novel antiviral is primary importance scientific community. this context, drug repurposing represents most used strategy; however, study host targets now attracting attention since it allows identification broad-spectrum endowed with high genetic barrier. last ten years our research group identified several small molecules DDX3X inhibitors and proved their efficacy against different viruses...

10.1021/acsmedchemlett.9b00681 article EN ACS Medicinal Chemistry Letters 2020-04-09
Coming Soon ...